GTBP · GT Biopharma, Inc. · Executive Compensation
$6.47
-0.41 (-5.89%)
At close · Sep 30
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year of the date that the financial statements are issued. In addition, the Company's independent registered public accounting firm, in its report on the Company's December 31, 2025 financial statements, raised substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$12.43M
Shares
1.80M
Volume · Sep 30
29.76K
Avg daily vol (16 sessions)
145.1K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Michael Breen | Chairman, Chief Executive Officer, and President | $1,727,646 |
| Alan Urban | Chief Financial Officer | $739,310 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Michael Breen | Chairman, Chief Executive Officer, and President | $1,186,972 |
| Alan Urban | Chief Financial Officer | $377,782 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Michael Breen | Executive Chairman of the Board of Directors and Interim Chief Executive Officer | $1,525,834 |
| Manu Ohri | Chief Financial Officer and Secretary | $1,129,671 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Michael Breen | Executive Chairman of the Board of Directors and Interim Chief Executive Officer | $1,892,293 |
| Manu Ohri | Chief Financial Officer and Secretary | $944,544 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Anthony Cataldo | Former Chief Executive Officer | $10,494,677 |
| Michael Breen | Executive Chairman of the Board of Directors and Interim Chief Executive Officer | $2,827,703 |
| Michael Handelman | Former Chief Financial Officer | $2,810,367 |
| Dr. Gregory Berk | Former Interim Chief Executive Officer, President of Research & Development and Chief Medical Officer | $1,424,519 |
| Dr. Gavin Choy | Former Acting Chief Financial Officer, Chief Clinical Development Officer | $961,818 |
| Manu Ohri | Chief Financial Officer and Secretary | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Anthony Cataldo | Former Chief Executive Officer | $428,817 |
| Michael Handelman | Former Chief Financial Officer | $74,833 |
| Dr. Gavin Choy | Former Acting Chief Financial Officer, Chief Clinical Development Officer | — |
| Dr. Gregory Berk | Former Interim Chief Executive Officer, President of Research & Development and Chief Medical Officer | — |
| Michael Breen | Executive Chairman of the Board of Directors | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| David C. Mun-Gavin | non-employee director of the Board | Appointed | 2025-06-11 |
| Andrew Ritter | member of the board of directors | Resigned | 2025-06-11 |
| Rajesh Shrotriya | member of the Board and all committees thereof | Resigned | 2025-05-13 |
| Andrew Ritter | non-employee director | Appointed | 2025-05-13 |
| Bruce Wendel | member of the Board and all committees thereof | Resigned | 2025-05-13 |
| Hilary Kramer | non-employee director | Appointed | 2025-05-13 |
| Michael Breen | Chief Executive Officer | Appointed | 2025-05-05 |
| Dr. Jeffrey Miller | Consulting Senior Medical Director | Appointed | 2024-09-16 |
| Alan L. Urban | Chief Financial Officer | Appointed | 2024-06-07 |
| Manu Ohri | Chief Financial Officer | Terminated | 2024-06-07 |
| Charles J. Casamento | member of the Board of Directors | Appointed | 2023-05-04 |
| Alan Urban | member of the Board of Directors | Resigned | 2023-05-04 |
| Dr. Gregory Berk | President of Research & Development and Chief Medical Officer | Terminated | 2022-12-13 |